Special Issues in Pharmacovigilance in Resource-Limited Countries
- Publisher's listprice EUR 85.59
-
35 498 Ft (33 808 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 20% (cc. 7 100 Ft off)
- Discounted price 28 399 Ft (27 046 Ft + 5% VAT)
- Discount is valid until: 31 December 2025
Subcribe now and take benefit of a favourable price.
Subscribe
35 498 Ft
Availability
Not yet published.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Springer Nature Singapore
- Date of Publication 2 October 2025
- Number of Volumes 1 pieces, Book
- ISBN 9789819661534
- Binding Hardback
- No. of pages377 pages
- Size 235x155 mm
- Language English
- Illustrations XV, 377 p. 20 illus., 18 illus. in color. Illustrations, black & white 700
Categories
Long description:
Examining the state of pharmacovigilance systems in resource-limited countries, this book addresses the critical role that pharmacovigilance systems play, as drugs and vaccines become increasingly accessible in these settings. Issues unique to these countries are explored, including medical product safety and quality problems, the nature of support needed to build pharmacovigilance system capacity to effective level, global and regional strategies and efforts to develop institutional and professional capacity; the challenges being faced and how these are being tackled.
This book is a must-read resource for anyone involved in the provision of safe, and quality medical products; and its rational use in resource-limited settings, including staff of pharmacovigilance centers, regulatory authorities, academia, contract research organizations, the pharmaceutical industry, donor agencies and technical assistance providers.
This book is unique in its focus on pharmacovigilance in resource-limited countries (RLCs). Many RLCs face serious challenges in maintaining health care systems, ensuring access to essential medicines and promoting drug safety. The editor has built an exceptional and well-balanced pharmacovigilance compendium. The individual chapters by experts provide a valuable resource of national and regional pharmacovigilance experiences. A very good read not only for pharmacovigilance professionals in RLCs, but also for donors and other international organisations.
Hubert G Leufkens, PhD, FISPE, Professor of Pharmaceutical Policy
and Regulatory Science, Utrecht Institute for Pharmaceutical Sciences (UIPS),
Former Head of the Dutch regulatory agency (MEB), The Netherlands
I foresee this collection will become a very useful reference for everyone working or supporting the development of pharmacovigilance in countries with limited resources. We have utilized the services of Dr. Ahmad on several occasions. His passion and focus on important issues resonates throughout the book.
Adel Al-Harf, PhD, Vice President of the Drug Sector,
Saudi Food and Drug Authority (SFDA), Kingdom of Saudi Arabia
Table of Contents:
"
1. Pharmacovigilance in Pakistan: A Neglected Link (Madeeha Malik, Azhar Hussain).- 2. Pharmacovigilance Situation in India: Issues and Challenges (J Vijay Venkatraman, Vignesh Rajendran and Ganesan Muniappan).- 3. Challenges and Opportunities for Pharmacovigilance Development in the Arab World (Danya M. Qato).- 4. What should be the Focus of Pharmacovigilance in the Pacific Island Countries? (John McEwen, Amanda L C Sanburg, Agnes Mathias, Lasse S Vestergaard).- 5. Pharmacovigilance and Public Health in Latin America Countries (Mónica Tarapués, Mariano Madurga).- 6. The Caribbean Network for Pharmacovigilance: Sharing Resources for Regional Vigilance (Rian Marie Extavour, Joy St John).- 7. The State of Pharmacovigilance in Brazil (Marcelo Vogler de Moraes and Yannie Silveira Gonçalves).- 8. What Signal Detection Means in a Small Database? - Case Reports from Cabo Verde (Veiga, Cálida Etezana Rodrigues).- 9. Pharmacovigilance Situation in Sierra Leone in the Light of the Ebola Crisis (Wiltshire C.N. Johnson, Onome T. Abiri).- 10. New Tuberculosis Drugs and the Role of Pharmacovigilance: Issues in Resource-limited Countries (EW. Tiemersma, S. van den Hof, M. Kimerling).- 11. The Public Health Issue of Falsified and Substandard Medicines in Resource-limited Settings (Céline Caillet and Paul N Newton).- 12. The Role of Pharmacovigilance Centers in Detecting Medication Errors: Moroccan Experience (Rachida Soulaymani Bencheikh, Loubna Alj, Ghita Benabdallah, Houda Sefiani).- 13. Pharmacovigilance Practices in Indian Systems of Medicine with Additional Highlights of its Concept in Unani Medicine (Syed Ziaur Rahman, Abdul Latif, Abdur Rauf, Sumbul Rehman).- 14. Vaccine Safety Issues in Resource-limited Countries (Daniel Weibel, Robert T. Chen, Osemeke Osokogu, Chioma Ejekam, Rebecca Chandler, Jyoti Joshi, Patrick Zuber, Steven Black, Silvia Perez-Vilar, Esperanca Sevene, Sammy Khagayi, Mandyam Ravi, Bruce Fireman, Laurence Baril, Sonali Kochhar, Jane Gidudu, Miriam Sturkenboom).- 15. Risk Perception and Communication in the Developing World (Bruce Hugman).- 16. Training and Capacity Building Opportunities in Pharmacovigilance (Karine Palin, Stéphane Liège, Christa Naboulet and Francesco Salvo).- 17. Pharmacy and Poisons Board: A Regional Centre of Regulatory Excellence (RCOREs) in Africa on Pharmacovigilance (Christabel Khaemba, Pamela Nambwa, Martha Mandale, Edward Abwao, Karim Wanga, Kariuki Gachoki, Fred M. Siyoi).- 18. KIDS-APEC Pharmacovigilance Center of Excellence Training (Euihwan Baek, E Na Song).- 19. Training and Capacity building Opportunities in Pharmacovigilance (Akiko Ogata).- 20. The UK MHRA’s Collaboration to Improve Pharmacovigilance in Resource-Limited Settings (Mick Foy).- 21. Pragmatic Pharmacovigilance and Combatting Substandard and Falsified Medical Products (SFs) (Paul B. Huleatt).- 22. Thirty Years of Safety and Vigilance Systems Strengthening in the WHO AFRO Region: from Buoyant Growth to Rigorous Protection of Public Health (Stanislav Kniazkov).- 23. Institutional and Individual Capacity Building in Pharmacovigilance (Tamara Hafner and Francis Aboagye-Nyame).- 24. Proforma Consortium to Strengthen Pharmacovigilance Capacity in Africa (Eleni Aklillu).- 25. Strengthening Pharmacovigilance in Africa - Pharmaco Vigilance Africa (PAVIA) (Frank GJ Cobelens; Michelle Nderu).
" More
AktG Aktiengesetz, Kommentar, 2 Bände: Kommentar
144 747 HUF